US 12,233,118 B2
Multivalent vaccine compositions and uses thereof
Jan Theunis Poolman, Vogelenzang (NL); Kellen Cristhina Fae, Oegstgeest (NL); Michal Sarnecki, Basel (CH); Jeroen Geurtsen, Vleuten (NL); Darren Robert Abbanat, Cornwall, NY (US); Bart Gustaaf M. Spiessens, Bierbeek (BE); and Frank Germaine F. Struyf, Bierbeek (BE)
Assigned to Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed by Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed on Sep. 17, 2021, as Appl. No. 17/478,584.
Claims priority of provisional application 63/079,734, filed on Sep. 17, 2020.
Claims priority of provisional application 63/191,471, filed on May 21, 2021.
Claims priority of application No. 21154782 (EP), filed on Feb. 2, 2021.
Prior Publication US 2022/0088165 A1, Mar. 24, 2022
Int. Cl. A61K 47/64 (2017.01); A61K 31/739 (2006.01); A61K 39/00 (2006.01); A61K 39/108 (2006.01)
CPC A61K 39/0258 (2013.01) [A61K 31/739 (2013.01); A61K 47/6415 (2017.08); A61K 47/646 (2017.08); A61K 2039/55583 (2013.01); A61K 2039/70 (2013.01)] 25 Claims
 
1. A composition comprising an E. coli O1 antigen polysaccharide covalently linked to a carrier protein, an E. coli O2 antigen polysaccharide covalently linked to a carrier protein, an E. coli O4 antigen polysaccharide covalently linked to a carrier protein, an E. coli O15 antigen polysaccharide covalently linked to a carrier protein, an E. coli O16 antigen polysaccharide covalently linked to a carrier protein, an E. coli O18 antigen polysaccharide covalently linked to a carrier protein, an E. coli O25 antigen polysaccharide covalently linked to a carrier protein, an E. coli O75 antigen polysaccharide covalently linked to a carrier protein and an E. coli O6 antigen polysaccharide covalently linked to a carrier protein, wherein:
(i) the E. coli O1 antigen polysaccharide is O1A antigen polysaccharide comprising the structure of Formula (O1A):

OG Complex Work Unit Chemistry
(ii) the E. coli O2 antigen polysaccharide comprises the structure of Formula (O2):

OG Complex Work Unit Chemistry
(iii) the E. coli O4 antigen polysaccharide is O4-Glc+ antigen polysaccharide comprising the structure of Formula (O4-Glc+):

OG Complex Work Unit Chemistry
(iv) the E. coli O6 antigen polysaccharide is O6A antigen polysaccharide comprising the structure of Formula (O6A):

OG Complex Work Unit Chemistry
(v) the E. coli O15 antigen polysaccharide comprises the structure of Formula (O15):
[→2)-β-D-Galp-(1→3)-α-L-FucpNAc-(1→3)-β-D-GlcpNAc-(1→]n,
(vi) the E. coli O16 antigen polysaccharide comprises the structure of Formula (O16):

OG Complex Work Unit Chemistry
(vii) the E. coli O18 antigen polysaccharide is O18A antigen polysaccharide comprising the structure of Formula (O18A):

OG Complex Work Unit Chemistry
(viii) the E. coli O25 antigen polysaccharide is O25B antigen polysaccharide comprising the structure of Formula (O25B):

OG Complex Work Unit Chemistry
 and
(ix) the E. coli O75 antigen polysaccharide comprises the structure of Formula (O75):

OG Complex Work Unit Chemistry
wherein the weight ratio of the E. coli antigen polysaccharides
O1:O2:O4:O6:O15:O16:O18:O25:O75 is about 1:1:1:1:1:1:1:2:2 and wherein each n is independently an integer of 1 to 100.